Purpose: To present the results of IntraLASIK treatment in myopic patients with nystagmus.
Methods: Four patients, ranging in age from 25 to 49 years, with congenital nystagmus (8 eyes), underwent IntraLASIK surgery. Corneal flaps were made by Intralase femtosecond laser. In some patients, the eyes were fixated with forceps or a fixation ring during the laser ablation. In all patients, the effect of involuntary eye movements was neutralized by an active tracking system.
Results: The refractive errors were corrected in all cases. There was no decentration or loss of best corrected visual acuity by more than 1 line. In 3 of 8 eyes, the post-operative uncorrected visual acuity (UCVA) was equal or better than the best spectacles corrected visual acuity (BSCVA) preoperatively. Four of the 8 eyes retained or improved their BSCVA.
Conclusions: Some patients with myopia and nystagmus may benefit from laser refractive surgery. By using the Intralase femtosecond laser and an active tracking system with or without mechanical fixation, laser refractive surgery may be safely and accurately performed in selected cases of nystagmus. Certain patients improve their BSCVA postoperatively.
Download full-text PDF |
Source |
---|
Jpn J Ophthalmol
January 2025
Department of Visual Science and Ophthalmology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Purpose: To review hospitalized patients with Acute Retinal Necrosis (ARN) and investigate factors associated with subsequent retinal detachment (RD).
Study Design: Retrospective.
Methods: The study included 40 patients (42 eyes), categorized into non-RD (23 eyes) and RD (19 eyes) groups.
BMC Ophthalmol
January 2025
Department of Ophthalmology, Linkou main branch, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Background: While vaccination remains crucial in mitigating the impact of the COVID-19 pandemic, several ocular adverse events has been reported, including Acute Zonal Occult Outer Retinopathy (AZOOR) complex.
Case Presentation: A 31-year-old female presented declined best corrected visual acuity (BCVA) and flashes in both eyes three days following second recombinant mRNA COVID-19 vaccine (Moderna). Fundus autofluorescence (FAF) illustrated speckled hyper-AF lesions surrounding right eye torpedo maculopathy site and hyper-AF lesions in the left macula.
BMC Ophthalmol
January 2025
Department of Optometry, School of Rehabilitation, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Background: The psychometric properties of the Convergence Insufficiency Symptom Survey (CISS) have been previously determined across the younger adult population. This study investigated the psychometric properties of the CISS in presbyopic adults via classical and Rasch analysis.
Methods: A total of 100 presbyopic individuals (40-60 years) were selected with far and near acuity of 20/20 with their habitual spectacles; 50 had convergence insufficiency and 50 had normal binocular vision.
J Neurosci
January 2025
Department of Ophthalmology, Harvard Medical School, Boston, MA, United States.
We employed high-resolution fMRI to distinguish the impacts of anisometropia and strabismus amblyopia on the evoked ocular dominance (OD) response. Sixteen amblyopic participants (8 females) plus 8 individuals with normal vision (1 female), participated in this study for whom, we measured the difference between the response to stimulation of the two eyes, across areas V1-V4.In controls, the evoked OD response formed the expected striped pattern within V1.
View Article and Find Full Text PDFBMJ Open Ophthalmol
January 2025
Ophthalmology & Vision Sciences, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Dual inhibition of the angiopoietin (Ang)/Tie and vascular endothelial growth factor (VEGF) signalling pathways in patients with retinal diseases, such as neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DME), may induce greater vascular stability and contribute to increased treatment efficacy and durability compared with treatments that only target the VEGF pathway. Faricimab, a bispecific intravitreal agent that inhibits both VEGF and Ang-2, is the first injectable ophthalmic drug to achieve treatment intervals of up to 16 weeks in Phase 3 studies for nAMD and DME while exhibiting improvements in visual acuity and retinal thickness. Data from real-world studies have supported the safety, visual and anatomic benefits and durability of faricimab, even in patients who were previously treated with other intravitreal agents.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!